Business
Maze Therapeutics Announces $150 Million Registered Offering
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price
About this update from Maze Therapeutics, Inc.
[{"type":"image","alt":"Maze Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Maze Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":189,"height":191,"url":"https://media.zenfs.com/en/globenewswire.com/57257613842a42ee3dc08323998b9e45"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Hg_UPK_c__tx4wmkY4a68g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2NA--/https://media.zenfs.com/en/globenewswire.com/57257613842a42ee3dc08323998b9e45","width":189,"height":191}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze.","length":947,"tagName":"p"},{"type":"text","content":"The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based healthcare-focused fund, a leading mutual fund, Frazier Life Sciences, Janus Henderson Investors, Deep Track Capital, and Driehaus Capital Management, as well as other healthcare dedicated funds.","length":389,"tagName":"p"},{"type":"text","content":"Leerink Partners LLC is acting as sole underwriter for the proposed offering.","length":77,"tagName":"p"},{"type":"text","content":"Maze currently intends to use any net proceeds from this offering primarily to advance research and development of its product candidates, including MZE829 for the treatment of APOL1-mediated kidney disease (AMKD) and MZE782 for the treatment of phenylketonuri...